Abstract
Background:
Sex, race and geographic location may affect vaccine-induced immune responses, yet few preventive HIV vaccine trials have systematically evaluated such effects. The main objective of this study was therefore to examine the role of these factors on vaccine-induced HIV-specific immune responses within the HVTN 204 trial. This randomized, double-blinded, placebo-controlled phase 2 trial enrolled 480 Black and Caucasian adults from Africa and the Americas, who received a trivalent DNA-HIV-1 vaccine prime followed by a rAd5 vector HIV-1 vaccine boost.
Methods:
Available serum samples from baseline and four weeks after the final vaccination boost from Black (n=85, 59% female) and Caucasian (n=49, 51% female) HVTN 204 vaccine recipients from South Africa and the United States of America were studied using an Enzyme-Linked Immunosorbent Assay to determine titers of Envelope-specific IgG1, IgG3 and IgA antibodies. Recognition of linear Envelope peptide-specific IgG responses was mapped in a randomly selected subgroup analysis using a custom-designed peptide microarray (n = 41, 49% female). Associations between vaccine-induced Envelope-specific antibody responses and sex assigned at birth (female or male), race and geographic location were then analyzed by the Mann-Whitney U test, Fisher’s exact test and multivariate logistic regression.
Results:
Four weeks post-final vaccination boost, we observed that Envelope-specific antibody titers were significantly increased for IgG1 but reduced for IgA in females (female vs. male median titer: 900 vs. 300, p=0.030 and <100 vs. 100, p=0.007, respectively). Multivariate logistic regression confirmed that female sex increased the odds for higher Envelope-specific IgG1 and low IgA titers compared to males. In terms of antibody epitopes, the V2 region was more frequently recognized in females than males (p=0.008). Race and geographic location had no apparent influence on antibody isotype titers investigated.
Conclusion:
Female sex was associated with higher vaccine-induced IgG Envelope-specific binding antibody titers and recognition of V2 region of HIV Envelope in HVTN 204 volunteers. No such associations were detected for race or geographic location. Understanding biological factors driving these sex-based differences may improve the design of a new generation of HIV vaccine candidates.
Introduction
Host genetics, sex and geographic location can influence immune responses to vaccines, such as measles, influenza and yellow fever (–). Some studies have suggested that Africans when compared to Caucasians have reduced HIV vaccine-induced immune responses after vaccination with HIV Envelope (Env) encoded in Adenoviral vectors (, ). African vaccinees also showed higher but less potent titers of HIV-neutralizing antibodies (Nab) against primary HIV-1 isolates compared to Caucasians, indicating that geographic location and/or race of vaccinees may influence vaccine-induced adaptive immune responses (). Of note, attempts to replicate RV144’s moderate HIV vaccine efficiency observed in the Thai volunteers in a South African (SA) high-risk cohort were unsuccessful (). Similarly, the recent “PrEPVacc” trial, which assessed the efficacy of two experimental HIV vaccine regimens in African populations was stopped after failing to demonstrate efficacy in preventing HIV acquisition (). HVTN 204 was a large multi-country, transcontinental, placebo-controlled phase 2 HIV vaccine trial conducted from 2008 to 2010 in the United States of America (US) and South Africa (SA), enrolling Black and Caucasian volunteers (). The vaccinees received a multiclade VRC-HIV DNA, followed by administration of a recombinant Adenoviral vectored vaccine rAd5-HIV. Vaccination was safe and induced T-cell and a high frequency of antibody responses to the vaccine-encoded HIV-Env and Gag antigens in 70% and over 80% of vaccinated volunteers, respectively (, ). While a similar vaccine in a follow-up study did not reduce the rate of HIV-1 acquisition in high-risk US volunteers (), the HVTN 204 study is optimally suited to address whether sex, geographic location and/or race can influence the immunoglobolin (Ig) isotype, epitope recognition patterns and/or magnitude of HIV vaccine-induced antibody responses.
Of note, IgG recognition of the V1V2 loop region of the HIV Env correlated with RV144 vaccine efficacy among Thai volunteers (–), while binding of plasma IgA antibodies to Env correlated directly with the rate of HIV-1 infection in RV144 vaccinees (). A plausible explanation is that while IgA is the most abundant antibody in mucosal sites, it can inhibit IgG mediated effector functions (, ). Differences in V1V2-specific IgG responses and IgA titers after HIV-1 vaccination between African and non-African vaccine recipients could therefore also hypothetically contribute to the failure of multiple recent phase 2b/3 vaccine trials in African populations.
Recently, we reported higher total immunoglobulin levels but similar IgG and IgA vaccine-induced responses to HIV-1 Env antigens in Black South Africans compared to US Caucasians in HVTN 204 trial participants after vaccination (). Therefore, we now examined the influence of race, sex and geographic location on the frequency, linear epitope specificity and isotypes of Env-specific antibody following DNA/rAd5 prime-boost vaccination during HVTN 204.
Methods
Study design and population
This study used a subset of serum samples from HVTN 204 – a randomized, double-blinded, placebo-controlled phase 2 clinical trial conducted from 2008 to 2010, which evaluated the safety and immunogenicity of a multiclade HIV-1 DNA vaccine, followed by a multiclade recombinant Adenoviral Vector HIV-1 vaccine boost in adults. HVTN 204 enrolled 480 male and female participants without HIV-1 from the Americas [US, Haiti, Jamaica, and Brazil] and SA (Clinicaltrials.gov: NCT00125970) (), making HVTN 204 amongst the earliest phase 2 HIV-1 vaccine trials that enrolled participants across different races and geographic locations. The male or female sex of participants was recorded as “sex assigned at birth”. Trial participants received either three multivalent DNA-HIV prime immunizations followed by a single rAd5-HIV boost immunization (n=240), or a placebo (n=240). Among vaccine recipients, 210 were from the US (n=90) and SA (n=120). This sub-study focused on analyzing available serum samples (n=134) from Black or Caucasian vaccinees in the US and SA that were collected in HVTN 204 at baseline and four weeks after the final vaccine boost (Supplementary Figure S1).
Ethics approval
Participants in HVTN 204 provided written informed consent for future use of their data and specimens. Approval for our use of the data and specimens was obtained from relevant ethics committees. Protocol approval details are as published by Churchyard et al. ().
Binding enzyme-linked immunosorbent assays
IgG1-, IgG3- and IgA-specific binding ELISA responses to a recombinant HIV-1 subtype C Envelope protein-CN54rgp140 were measured in serum samples at baseline, and at four weeks post-final vaccination boost, in a 3-fold (for IgG isotypes) or 5-fold (for IgA) dilution series as previously described by Joachim et al. (). Absorbance (optical density = OD) was read immediately at 450 nm using an ELISA plate reader (Tecan, San Jose, US). A sample was considered positive for anti-CN54rgp140 IgG isotypes at 1: 100 or 1: 300 dilutions if the mean OD value was more than twice that of the pre-immunization sample at 1:100 or 1:300 dilutions, respectively. A sample was considered positive in a dilution >1:300 if the absorbance value was more than twice the mean of the pre-immunization sample run at a 1:300 dilution. A positive vaccine-induced IgA response was defined as mean OD at 1: 100 or 1: 500 dilutions being more than twice that of the pre-immunization sample at 1:100 or 1:500 dilutions, respectively. A sample was also considered as positive for anti-CN54rgp140 IgA at a dilution >1:500 if the absorbance value was more than twice the mean of the pre-immunization sample run at a 1:500 dilution. Data were reported as reciprocal end-point titers (end-point titer being the last dilution at which a sample shows a positive response).
Peptide array
A peptide microarray (JPT, Berlin) approach was used to assess IgG binding to the HIV-1 Env peptides as described previously by Horvath et al. (). In brief, our custom microarray included 1034 overlapping linear 15-mer peptides to map the gp160 extracellular domain of the HIV-1 Env protein. The array backbone consists of 10 full-length Env immunogen sequences. Additionally, 15 previously identified immunodominant regions were covered by additional peptide variants of all HIV-1 clades covering the current epidemic. We measured serum samples from baseline and four weeks after final vaccination at a dilution of 1:100. Fluorescence signals were measured with a GenepixPro Scanner, 6.0 software (Molecular Devices, San José, CA, US) and converted into numeric intensity values with a maximum of 60000. Each peptide was assigned the correct position on the gp160 scaffold with the corresponding fluorescence intensity (FI) value. For the assignment to the gp160 alignment, we used a fasta file containing both the sequences of the array and the immunogen sequences of the HVTN 204 trial. For further analysis of peptide array IgG binding data, baseline values were subtracted from post-vaccination values using R studio (version 1.4.1106) and Microsoft Excel. To exclude background signals, we used a cut-off for positive signals of 2500 FI. Mean FI values per study group were calculated if at least 25% of the vaccinees showed a positive binding response against the respective peptide. Immunodominant regions (IDR) were defined by frequent (FOR of > 50%) and strong (mean FI > 10000) recognition of peptides in at least one of the four groups (US female, US male, SA female, SA male). If more than one overlapping peptide was recognized, the epitope with the higher response was selected for statistical analysis.
Statistical analysis
Stata version 17 (StataCorp, US), Microsoft Excel (Microsoft, US), R version 4.x (R Core Team, 2024) and GraphPad Prism version 9 (GraphPad Software Inc, US) were used for statistical analysis. Two-tailed Mann-Whitney U test was done to compare titers or peptide recognition across participants’ sex, geographic location and race. The median age between females and males was also analyzed by Mann-Whitney U test. Fisher’s exact test was used in the comparison of all categorical analyses. Logistic regression was done to investigate the association between sex, age, and race with the frequency of positive antibody responses. Model fitness was assessed by Hosmer–Lemeshow Test whereby a model was considered a good fit if the p-value was greater than 0.05 for all models.
Results
Description of the cohort
A summary of the geographic location, age, sex, and race of study participants is provided in Table 1. Serum samples from 134 age- and sex-matched vaccinated participants with a median age of 26 years were analyzed. Over half (56%) were female, nonetheless, males and females had similar demographic characteristics (Table 1).
Table 1
| Variable | All (134) [n, (column %)] | Female (75) [n, (column %)] | Male (59) [n, (column %)] | P-value | |
|---|---|---|---|---|---|
| Country | US | 61 (45.5%) | 31 (41.3%) | 30 (50.9%) | 0.298a |
| South Africa | 73(54.5%) | 44 (58.7%) | 29 (49.1%) | ||
| Age, median (IQR) | 26 (22-33) | 26 (22-31) | 25 (22-36) | 0.554b | |
| Race | Black | 85 (63.4%) | 50 (66.7%) | 35 (59.3%) | 0.470a |
| Caucasian | 49 (36.6%) | 25 (33.3%) | 24 (40.7%) | ||
Baseline demographic characteristics (n=134).
Statistical tests: aFisher’s exact test, bMann-Whitney U test.
Females and Black Africans have increased IgG1 background signals
We first analyzed the background levels (at 1:100 dilution) of our anti-CN54rgp140 IgG and IgA antibody testing approaches at baseline, prior to the first vaccination in HVTN 204. Regardless of sex, race or geographical location and despite low pre-vaccination ODs, 32% (37/115), 54% (73/134) and 86% (90/105) of all pre-vaccinated individuals had 2-fold or higher ODs when compared to blank ODs for IgG1, IgG3 and IgA, respectively. Upon stratification by sex, females had a 1.8 times higher median IgG1 background signal compared to males (median OD: 0.062 vs 0.034, p = 0.011, Figure 1, left panel). Furthermore, Black South Africans had comparable pre-vaccination anti-CN54rgp140 binding IgG1 OD values when compared to Caucasians but slightly increased when compared to Black Americans (median IgG1 OD: 0.053 vs 0.025, p = 0.097, Figure 1, right panel). In South Africa, Black females had significantly higher background signals of anti-CN54rgp140 IgG1 compared to Black males (p = 0.011, Supplementary Figure S2).
Figure 1
Sex influences isotype profile of vaccine-induced antibody responses
Next, we analyzed IgG (IgG1 and IgG3) and IgA titers to subtype C CN54rgp140 at 4 weeks post-final vaccine boost. While vaccine-induced anti-CN54rgp140 binding IgG1 and IgG3 antibodies were present in most participants (IgG1: 85.2% and IgG3: 88.0%, Table 2), IgA antibodies were detected in only 34% of vaccinees. A significantly higher proportion of female participants showed anti-CN54rgp140 IgG1 responses than males (92.3% vs 76.0%, p=0.018, Table 2). On the contrary, a low proportion of females mounted detectable anti-CN54rgp140 IgA responses compared to males (22.6% vs 51.2%, p=0.003, Table 2). Consistent with these findings, we also observed significantly higher anti-CN54rgp140 IgG1 and lower anti-CN54rgp140 IgA titers in females compared to males (anti-CN54rgp140 IgG1 median titers: 900 (IQR:300-1800) vs 300 (IQR:75-900, p=0.030); anti-CN54rgp140 IgA median titers: <100 (IQR: <100 -<100) vs 100 (IQR: <100 -500), p=0.007, Figure 2, left panels).
Table 2
| Antibody Isotype | All [n, (%)] | Female [n, (%)] | Male [n, (%)] | P-value* |
|---|---|---|---|---|
| IgG1 | 98/115 (85.2%) | 60/65 (92.3%) | 38/50 (76.0%) | 0.018 |
| IgG3 | 118/134 (88.0%) | 69/75 (92.0%) | 49/59 (83.0%) | 0.178 |
| IgA | 36/105 (34.3%) | 14/62 (22.6%) | 22/43 (51.2%) | 0.003 |
Frequency of antibody responses to subtype C CN54rgp140 per isotype at four weeks post-final vaccination boost.
*Fisher’s exact test. Bold values indicate statistical significance (p<0.05).
Figure 2
When IgG1, IgG3 and IgA titers were compared in vaccinated individuals stratified by race and geographic location, we observed similar median titers for all antibody sub-classes across all groups (Figure 2, right panels). When further stratified by sex and geographic location, significantly higher anti-CN54rgp140 IgA titers were observed in South African males than in South African females (median: 100 vs <100, p = 0.042, Supplementary Figure S3).
HIV-1 Env epitope recognition varies by geographic location and sex
To determine IgG antibody epitope specificity within the HIV-1 Env, peptide array analysis was conducted on a subgroup of 21 Black South Africans and 20 US Caucasian participants with equal proportions of males and females (Supplementary Table S1). Four prominent IDRs, as defined by high frequency of recognition and signal intensity, were detected after final vaccination boost: one within C1 (IDR1_C1; HxB2 gp160 pos 107-121; DIISLWDQSLKPCVK), another in V2 (IDR2_V2; HxB2 gp160 pos 163-177; TSIRGKVQKEYAFFY), followed by V3 (IDR3_V3; HxB2 gp160 pos 304-318; RKRIRIQRGPGRAFV), and finally, gp41 (IDR4_gp41; HxB2 gp160 pos 580-594; ILAVERYLKDQQLLG) (Supplementary Figure S4). While IDR3_V3 was the most immunodominant among these, IDR1_C1 exhibited higher frequency and intensity of recognition among participants from the US (response in 9/20; mean FI 15,008) than from South Africa (response in 4/21; mean FI 2,243) (p = 0.077; Figure 3A). Recognition of IDR1_C1 was slightly stronger in females (response in 7/20; mean FI 12,770) than males (response in 6/21; mean FI 4,374). Significant sex-specific differences were detected for IDR2_V2-specific responses, a region associated with protective immunity in RV144 (), which demonstrated more frequent recognition in females (response in 7/20; mean FI 13,568) compared to males (response in 3/21; mean FI 1,629; p = 0.008; Figure 3B) across both the US and South African cohorts. Additionally, IDR3_V3 exhibited slightly stronger recognition among participants from the US (mean FI 41,874) than from South Africa (mean FI 28,760; p = 0.045; Figure 3C). Interestingly, IDR3_V3 – an epitope usually recognized with high frequency and intensity - was poorly recognized only in South African males (mean FI 23,600). Recognition of a linear epitope covering the start of the immunodominant region within gp41 (IDR4_gp41) did not show significant variation across the HVTN 204 participants (Figure 3D).
Figure 3
Sex but not age, geographic location or race affects the frequency of HIV vaccine antibody responses
Multivariate logistic regression was performed to evaluate the effects of sex, age, and race on the frequency of detectable antibody responses per isotype (Figure 4). For IgG1, females had 3.9 increased odds of a positive antibody response compared to males (95% CI: 1.33 – 13.32, p = 0.018). Interestingly, the opposite was observed for IgA where females had 74% lower odds for positive antibody response (95% CI: 0.11 – 0.62, p = 0.003). Of note, IgG3 was not affected by any of the aforementioned factors. Age and race had no statistically significant association with the frequency of antibody immune response for any of the analyzed immunoglobins.
Figure 4
Discussion
Differences in Env-V1V2-specific IgG responses and Env-specific IgA titers after HIV vaccination between African and non-African vaccine recipients may have potentially contributed to the failure of multiple recent phase 2b/3 vaccine trials in African populations. We herein investigated the influence of race, geographic origin and sex in HVTN 204 vaccinees who received a VRC-HIV-DNA prime plus rAd5-HIV boost vaccine regimen on the Env-specific humoral immune response. An overall high frequency of vaccine-induced subtype C CN54rgp140 IgG1 and IgG3 responses were detected four weeks after final vaccination, with comparable titers of anti-CN54rgp140 and anti-IDR3_V3 IgG antibodies when results were stratified by race (Black Africans vs Caucasian Americans) or by geographic location (South Africa vs US). However, female sex was associated with increased systemic anti-CN54rgp140 IgG1, as well as a higher magnitude of IDR2_V2-specific IgG recognition compared to males.
These data are consistent with a recent meta-analysis of multiple HIV-1 vaccine regimens which reported that female sex is a strong predictor for a high HIV Env IgG responder status (). Further, females are known to have 40% less HIV plasma viremia than males (). This is relevant as increased vaccine-induced SIV-specific IgG isotypes levels have been linked with partial protection from SIV acquisition and reduced peak viremia in female macaques in pre-clinical HIV/SIV models (). We also frequently observed no or very low levels of serum anti-CN54rgp140 IgA responses, especially in vaccinated females compared to males. In the RV144 clinical trial, reduced systemic levels of IgA correlated with reduced risk for HIV-1 acquisition (). It was hypothesized that IgA antibodies can compete with IgG for HIV-1 Envelope antibody binding sites, thereby reducing antibody-mediated effector functions such as antibody-dependent cellular cytotoxicity (). Our data therefore do not support the hypothesis that differences in vaccine-induced humoral immune responses between racial or geographic groups contributed to the failure of the HVTN 702 and 705 HIV vaccine efficacy trials, which were conducted primarily among young African women at high risk of HIV infection (, ).
Higher levels of vaccine- and infection-induced immunity in females have also been previously reported (, –). For example, females generally mount a higher strain-specific antibody responses to influenza vaccine and a better vaccine efficacy (as measured by hospitalization and mortality rate) than males (–). Here we extend these findings to more novel vaccine approaches using naked DNA prime and an Adenoviral vector boost. Differences in sex hormones and the fact that various immune-related genes are X-linked with greater activation in females than males due to females possessing two X-chromosomes may contribute to the differences observed in our study (, , 31). Nonetheless, it is important to note that factors other than female sex do play a significant role in infection dynamics. The South African HVTN 702 trial reported over a 3-fold increased cumulative risk for HIV acquisition in women when compared to men despite mounting high titers of functional anti-gp120 and anti-gp140 antibodies. The increased risk was likely attributed to increased genital inflammation resulting from sexually transmitted infections coupled with socioeconomic vulnerabilities that expose women to an increased “risky” lifestyle and a greater force of HIV infection compared to men (). Our finding of elevated pre-vaccination anti-CN54rgp140-specific IgG1 titers, particularly in female vaccinees from South Africa has also been previously reported by others (32–35) and may stem from antibody cross-reactivity resulting from exposure to environmental antigens such as the intestinal microbiome or others (36).
People of Black African origin living with HIV have been reported to have higher HIV-specific IgG levels than Caucasian Americans with HIV (37). However, only a few clinical trials have systematically compared differences in the induction of HIV-specific antibodies between Black Africans and Caucasians during HIV clinical trials (, 38–40). We have recently reported similar vaccine-induced IgG and IgA titers against consensus B Envelope antigens/HIV antigens from non-clade C isolates amongst South Africans, African Americans, and Caucasians from the US who participated in the HVTN 204 trial (). Here, we extend these findings and show comparable titers of anti-CN54rgp140 binding antibodies isotypes between Black people from any of the studied geographic regions and Caucasians from the US following immunization with the same vaccine regimen.
The epitope specificity of anti-HIV-1 Env antibodies elicited in HVTN 204 trial participants aligns with previous observations for this vaccine regimen (). RV172 trial participants in East Africa, receiving the same VRC-HIVDNA and rAd5-HIV vaccine combination as HVTN 204 participants (41), recognized the same Env regions in C1, V3, and gp41 (). IDR2_V2 responses, however, were largely absent in RV172 participants studied in Horvath et al. (). Intriguingly, IgG responses targeting the linear IDR2_V2 epitope (HXB2 163-177) were previously detected only following immunization regimens including clade E- or AE-based immunogens (, , 42–44), whereas the HVTN 204 vaccine regimen is composed of Env glycoproteins from clades A, B and C (). Unfortunately, demographic data for the participants studied during previous peptide array analyses were unavailable, precluding commentary on sex biases in Env responses within the analyzed trials (, , 42, 45–48). Nevertheless, in contrast to the more frequent IDR2_V2 responses in females observed for HVTN 204, V2 responses were highly frequent in the all-male participants of the Vax003 trial, which tested a monomeric gp120 immunogen (). Additionally, in RV144, no correlation was found between immune responses associated with protection and sex (), highlighting the need for further exploration of sex and race disparities in vaccine-induced antibody epitope specificity and to disentangle individual effects of demographic variables.
Limitations of this study include a small sample size due to the unavailability of a third of the targeted samples from the HVTN 204 trial at the time of analysis. While the sample size is limited, we identified the HVTN 204 trial as best suited for our purpose, as phase 2 vaccine trials are typically conducted only on a single continent. Peptide array analysis only focused on Black Africans and US Caucasians because of limited availability of custom peptide arrays at the time. Moreover, this assay only detects antibodies to linear, non-glycosylated epitopes but not conformational ones. A greater sample size would enable a more powerful statistical multivariate analysis. Future studies should therefore optimally explore the effects of race, geography and sex on vaccine-induced neutralizing antibody and cell-mediated immune responses in larger cohorts. Nonetheless, despite the small sample size, we were able to show a significant influence of sex on vaccine-induced IgG Env-specific binding antibody titers and recognition of certain Env regions in HVTN 204, that associated with protection during the RV144 trial (, ). Hence, these findings shed more light on our understanding of the influence of sex in determining the immunogenicity of DNA and/or Adenoviral vector vaccine approaches for HIV and potentially extending to other pathogens.
Conclusion
In conclusion, female sex was most associated with differences in the vaccine-induced HIV-Env-specific antibody response, while these differences were less prominent when stratifying assay results for HVTN 204 participants by geographic location or race. Thus, biological factors driving these sex-based differences should be further examined in other HIV vaccine-induced humoral and cell-mediated responses.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by institutional review boards at each of the participating sites: Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho Faculdade de Medicina for the Rio, Brazil site; Secretaria de Estado da Saúde, Coordenadoria de Controle de Doenças Centro de Referência e Treinamento DST/AIDS for the Sao Paulo, Brazil site; Comité des Droits Humains des Centres GHESKIO; Ministère de la Santé Publique et de la Population National Ethics Committee and Weill Cornell Medical College, Human Research Protection Programs, Division of Research Integrity for the Port au Prince, Haiti site; Ministry of Health and Environment, Standards & Regulations Division; University of the West Indies Ethics Committee for the Kingston site; University of Alabama at Birmingham IRB for the Birmingham, AL site; Partners Human Research Committee for the Boston, MA (Brigham & Women’s) site; Miriam Hospital, Office of Research Administration Communications and Committee Review for the Providence, RI site; Vanderbilt IRB for the Nashville, TN site; University of Rochester Research Subjects Review Board for the Rochester, NY site, University of Maryland, School of Medicine IRB for the Baltimore, MD (IHV) site; University of Kwazulu-Natal, Biomedical Research Ethics Administration for the Klerksdorp, South Africa site; University of Cape Town, Health Sciences Faculty Research Ethics Committee for the Cape Town, South Africa site; and University of the Witwatersrand, Johannesburg, Human Research Ethics Committee for the Soweto, South Africa site. The study was also approved by each country’s Regulatory agency and was reviewed by the US Food and Drug Administration before being allowed to proceed. All study participants provided written informed consent prior to participation. The trial is registered at ClinicalTrials.gov, registration NCT00125970. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
WM: Methodology, Data curation, Visualization, Investigation, Writing – review & editing, Writing – original draft. AH: Writing – review & editing, Visualization, Writing – original draft, Formal analysis, Data curation. KH: Supervision, Data curation, Conceptualization, Writing – review & editing, Visualization, Writing – original draft, Formal analysis. LM: Supervision, Writing – original draft, Writing – review & editing, Conceptualization. MH: Conceptualization, Supervision, Writing – review & editing, Writing – original draft. L-GB: Writing – review & editing, Writing – original draft, Investigation. AD: Investigation, Writing – original draft, Writing – review & editing. ZM: Writing – review & editing, Writing – original draft, Investigation. GC: Writing – original draft, Writing – review & editing, Investigation. MK: Writing – review & editing, Investigation, Writing – original draft. EV: Supervision, Writing – original draft, Conceptualization, Writing – review & editing. CM: Supervision, Conceptualization, Investigation, Writing – review & editing, Writing – original draft. CG: Conceptualization, Investigation, Writing – review & editing, Supervision, Writing – original draft. MC: Data curation, Conceptualization, Supervision, Methodology, Writing – review & editing, Investigation, Writing – original draft, Formal analysis, Visualization.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. This study was funded by the National Institute of Allergy and Infectious Diseases (NIAID), through HVTN Initiatives Program (Subaward N°0000924089). Peptide array mapping analysis was further supported by the European HIV Vaccine Alliance (EHVA; EC Horizon 2020, grant number 681032) and the German Center for Infection Research (DZIF international clinical trials unit-HIV: TTU04.708). AH was supported by a DZIF MD Stipend (TI 07.003). The initial HVTN 204 clinical trial was funded by grants from the National Institutes of Health (NIH) to the following respective institutions: AI046747/AI068614 (HVTN Core); AI046703/AI068635 (HVTN SCHARP); AI046725/AI068618 (HVTN Laboratory program); AI047996/AI069452 (University of Alabama at Birmingham); AI048001/AI069447 (University of Maryland Baltimore); AI048023/AI069412 (Brigham and Women’s Hospital, Miriam Hospital); AI047980/AI069511 (University of Rochester); AI047985/AI069439 (Vanderbilt University); AI046747 (Centro de Referencia e Treinamento-DST/AIDS, ERTU, Klerksdorp, Desmond Tutu HIV Center at Cape Town, Hospital Escola Sao Francisco de Assi, and Perinatal HIV Research Unit); AI069420 (Centro de Referencia e Treinamento-DST/AIDS); AI069409 Epidemiology Research and Training Unit (ERTU); AI069469 (Klerksdorp); AI069519 (Desmond Tutu HIV Center); AI069414 (Hospital Escola Sao Francisco de Assi); AI069453 (Perinatal HIV Research Unit); 30022/1U01AI069421/U01AI046747 (GHESKIO).
Acknowledgments
Special gratitude goes to all HVTN 204 study participants. We are grateful to Edger Chalamila, Lumuli Mwakanjuki, and Claudia Bräu-Heberger for their technical expertise. We also thank Georgios Pollakis for his expert input in peptide array design.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1601865/full#supplementary-material
Supplementary Figure 1HVTN 204 trial participants from the vaccine arm with respect to country (United States of America vs South Africa) and race (Black vs Caucasian) who participated in this study.
Supplementary Figure 2South African females have increased anti-CN54rgp140-specific IgG1 background signal. Optical densities (OD) in participants with background signal pre-vaccination (A) IgG1 (n=37), (B) IgG3 (n=73) and (C) IgA (n=90) stratified by sex, race and geographical region. Each dot represents one individual; round dots indicate males and triangles represent females. Median lines are indicated in graphs. Statistical analysis was performed using the Mann-Whitney U-test.
Supplementary Figure 3Magnitude of anti-CN54rgp140-specific IgG1, IgG3 and IgA titers stratified by geographic location, sex and race of vaccinated participants. Antibody titers in vaccinated participants for (A) IgG1 (n = 115), (B) IgG3 (n = 134) and (C) IgA (n = 105) stratified by sex, race and geographical region. Each dot represents one individual; round dots indicate males and triangles represent females. Median lines are indicated in graphs. Statistical analysis was performed using the Mann-Whitney U-test.
Supplementary Figure 4HIV-1 Env recognition of HVTN 204 participants shows four immunodominant epitopes. IgG epitope recognition along the HIV-1 Env protein for all participant groups. The frequency of responders (FOR; upper panel) and the mean fluorescence intensities (mean FI; lower panel) plotted against individual antigenic regions along the entire HIV-1 Env as included in the 10 full-length Env immunogen sequences comprising the array backbone. Each row of the respective heat maps displays the Env-specific IgG responses of HVTN 204 participants stratified by geographic location and sex, tested four weeks after the last vaccination. IgG responses against individual antigenic regions were considered positive if the corresponding FI was above 3,500 after subtraction of the pre-vaccination value. The mean FI was calculated using the maximum FI values per position for each participant, only if peptide-specific IgG responses occurred in at least 25% of the vaccinees. IDRs 1–4 are indicated by red lines.
References
1
PosteraroBPastorinoRDi GiannantonioPIanualeCAmoreRRicciardiWet al. The link between genetic variation and variability in vaccine responses: Systematic review and meta-analyses. Vaccine. (2014) 32:1661–9. doi: 10.1016/j.vaccine.2014.01.057
2
KleinSLMarriottIFishEN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. (2015) 109:9–15. doi: 10.1093/trstmh/tru167
3
van DorstMMARPyuzaJJNkurunungiGKullayaVISmitsHHHogendoornPCWet al. Immunological factors linked to geographical variation in vaccine responses. Nat Rev Immunol. (2023) 24:1–14. doi: 10.1038/s41577-023-00941-2
4
MontefioriDCMetchBMcElrathMJSelfSWeinholdKJCoreyLet al. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis. (2004) 190:1962–9. doi: 10.1086/425518
5
BadenLRKaritaEMutuaGBekkerLGGrayGPage-ShippLet al. Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: A randomized trial. Ann Intern Med. (2016) 164:313–22. doi: 10.7326/M15-0880
6
GrayGEBekkerLGLaherFMalahlehaMAllenMMoodieZet al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120/MF59 in adults. N Engl J Med. (2021) 384:1089–100. doi: 10.1056/NEJMoa2031499
7
News Release: Experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition, PrEPVacc study reports. PrEPVacc (2023). Available online at: https://www.prepvacc.org/news/experimental-hiv-vaccine-regimens-likely-to-be-ineffective-6-dec-2023-news-release. (Accessed September 5, 2025)
8
ChurchyardGJMorganCAdamsEHuralJGrahamBSMoodieZet al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One. (2011) 6:e21225. doi: 10.1371/journal.pone.0021225
9
HammerSMSobieszczykMEJanesHKarunaSTMulliganMJGroveDet al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. (2013) 369:2083–92. doi: 10.1056/NEJMoa1310566
10
YatesNLLiaoHXFongYdeCampAVandergriftNAWilliamsWTet al. Vaccine-induced env V1–V2 igG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. (2014) 6:228ra39. doi: 10.1126/scitranslmed.3007730
11
ChungAWGhebremichaelMRobinsonHBrownEChoiILaneSet al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med. (2014) 6:228ra38. doi: 10.1126/scitranslmed.3007736
12
TayMZLiuPWilliamsLDMcRavenMDSawantSGurleyTCet al. Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses. PLoS Pathog. (2016) 12:e1005817. doi: 10.1371/journal.ppat.1005817
13
HaynesBFGilbertPBMcElrathMJZolla-PaznerSTomarasGDAlamSMet al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. (2012) 366:1275–86. doi: 10.1056/NEJMoa1113425
14
GottardoRBailerRTKorberBTGnanakaranSPhillipsJShenXet al. Plasma igG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One. (2013) 8:e75665. doi: 10.1371/journal.pone.0075665
15
TomarasGDFerrariGShenXAlamSMLiaoHXPollaraJet al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A. (2013) 110:9019–24. doi: 10.1073/pnas.1301456110
16
SeatonKEDealAHanXLiSSClaytonAHeptinstallJet al. Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. NPJ Vaccines. (2021) 6:1–11. doi: 10.1038/s41541-021-00305-8
17
LinLYFerteTChachageMCasteanoCLaumondGSchmidtSet al. Deciphering HIV vaccine-induced antibody response according to ethnicity. AIDS. (2025) 39:957. doi: 10.1097/QAD.0000000000004196
18
JoachimABauerAJosephSGeldmacherCMunseriPJAboudSet al. Boosting with subtype C CN54rgp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA is safe and enhances immune responses: A phase I trial. PLoS One. (2016) 11:e0155702. doi: 10.1371/journal.pone.0155702
19
HorvathARogersLPollakisGBaranovOJosephSChachageMet al. Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability? Front Immunol. (2023) 13:1075606/full. doi: 10.3389/fimmu.2022.1075606/full
20
HuangYZhangYSeatonKEDe RosaSHeptinstallJCarppLNet al. Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens. eBioMedicine. (2022) 84:104271. doi: 10.1016/j.ebiom.2022.104271
21
MoranJATurnerSRMarsdenMD. Contribution of sex differences to HIV immunology, pathogenesis, and cure approaches. Front Immunol. (2022) 13. Available online at: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.905773/full. (Accessed September 5, 2025)
22
MohanramVDembergTMusichTTueroIVargas-InchausteguiDAMiller-NovakLet al. B cell responses associated with vaccine-induced delayed SIVmac251 acquisition in female rhesus macaques. J Immunol Baltim Md. (1950) 197:2316–24. doi: 10.4049/jimmunol.1600544
23
Rerks-NgarmSPitisuttithumPNitayaphanSKaewkungwalJChiuJParisRet al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. (2009) 361:2209–20. doi: 10.1056/NEJMoa0908492
24
GrayGEMngadiKLavreysLNijsSGilbertPBHuralJet al. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Infect Dis. (2024) 24:1201–12. doi: 10.1016/S1473-3099(24)00358-X
25
Miller-NovakLKDasJMusichTADembergTWeinerJAVenzonDJet al. Analysis of complement-mediated lysis of simian immunodeficiency virus (SIV) and SIV-infected cells reveals sex differences in vaccine-induced immune responses in rhesus macaques. J Virol. (2018) 92:e00721–18. doi: 10.1128/JVI.00721-18
26
KleinSLFlanaganKL. Sex differences in immune responses. Nat Rev Immunol. (2016) 16:626–38. doi: 10.1038/nri.2016.90
27
FlanaganKLFinkALPlebanskiMKleinSL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. (2017) 33:577–99. doi: 10.1146/annurev-cellbio-100616-060718
28
EnglerRJMNelsonMRKloteMMVanRadenMJHuangCYCoxNJet al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. (2008) 168:2405–14. doi: 10.1001/archinternmed.2008.513
29
WangCSWangSTChouP. Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community. Vaccine. (2002) 20:2494–9. doi: 10.1016/S0264-410X(02)00181-0
30
HarperAFlanaganKL. Effect of sex on vaccination outcomes: important but frequently overlooked. Curr Opin Pharmacol. (2018) 41:122–7. doi: 10.1016/j.coph.2018.05.009
31
SciarraFCampoloFFranceschiniECarlomagnoFVenneriMA. Gender-specific impact of sex hormones on the immune system. Int J Mol Sci. (2023) 24:6302. doi: 10.3390/ijms24076302
32
NguyenMPeanPLopalcoLNouhinJPhoungVLyNet al. HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J Acquir Immune Defic Syndr. (1999) 42:412–9. doi: 10.1097/01.qai.0000222289.97825.35
33
BrownLSouberbielleBEMarriottJBWestbyMDesselbergerUKayeTet al. The conserved carboxy terminal region of HIV-1 gp120 is recognized by seronegative HIV-exposed people. AIDS. (1999) 13:2515. doi: 10.1097/00002030-199912240-00004
34
CarrilloJRestrepoCRallónNIMassanellaMdel RomeroJRodríguezCet al. HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. AIDS. (2013) 27:1375. doi: 10.1097/QAD.0b013e32835fac08
35
MesteckyJWrightPFLopalcoLStaatsHFKozlowskiPAMoldoveanuZet al. Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses. (2011) 27:469–86. doi: 10.1089/aid.2010.0169
36
WilliamsWBLiaoHXMoodyMAKeplerTBAlamSMGaoFet al. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science. (2015) 349:aab1253. doi: 10.1126/science.aab1253
37
McGowanJPShahSSSmallCBKleinRSSchnipperSMChangCJet al. Relationship of serum immunoglobulin and IgG subclass levels to race, ethnicity and behavioral characteristics in HIV infection. Med Sci Monit Int Med J Exp Clin Res. (2006) 12:CR11–16.
38
RusertPKouyosRDKadelkaCEbnerHSchanzMHuberMet al. Determinants of HIV-1 broadly neutralizing antibody induction. Nat Med. (2016) 22:1260–7. doi: 10.1038/nm.4187
39
TomarasGDPlotkinSA. Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev. (2017) 275:245–61. doi: 10.1111/imr.12514
40
GrayGEHuangYGrunenbergNLaherFRouxSAndersen-NissenEet al. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. (2019) 11:eaax1880. doi: 10.1126/scitranslmed.aax1880
41
KibuukaHKimutaiRMabokoLSaweFSchunkMSKroidlAet al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected east africans (RV 172). J Infect Dis. (2010) 201:600–7. doi: 10.1086/650299
42
NadaiYHeldKJosephSAhmedMIMHoffmannVSPeterhoffDet al. Envelope-specific recognition patterns of HIV vaccine-induced igG antibodies are linked to immunogen structure and sequence. Front Immunol. (2019) 10. Available online at: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00717/full. (Accessed May 20, 2025)
43
MsafiriFJoachimAHeldKNadaiYChissumbaRMGeldmacherCet al. Frequent anti-V1V2 responses induced by HIV-DNA followed by HIV-MVA with or without CN54rgp140/GLA-AF in healthy african volunteers. Microorganisms. (2020) 8:1722. doi: 10.3390/microorganisms8111722
44
ShenXLaherFMoodieZMcMillanASSprengRLGilbertPBet al. HIV-1 vaccine sequences impact V1V2 antibody responses: A comparison of two poxvirus prime gp120 boost vaccine regimens. Sci Rep. (2020) 10:2093. doi: 10.1038/s41598-020-57491-z
45
KratochvilSMcKayPFKopycinskiJTBishopCHayesPJMuirLet al. A phase 1 human immunodeficiency virus vaccine trial for cross-profiling the kinetics of serum and mucosal antibody responses to CN54gp140 modulated by two homologous prime-boost vaccine regimens. Front Immunol. (2017) 8:595. doi: 10.3389/fimmu.2017.00595
46
JosephSQuinnKGreenwoodACopeAVMcKayPFHayesPJet al. A Comparative phase I study of combination, homologous subtype-C DNA, MVA, and env gp140 protein/adjuvant HIV vaccines in two immunization regimes. Front Immunol. (2017) 8:149. doi: 10.3389/fimmu.2017.00149
47
JoachimAAhmedMIMPollakisGRogersLHoffmannVSMunseriPet al. Induction of identical igG HIV-1 envelope epitope recognition patterns after initial HIVIS-DNA/MVA-CMDR immunization and a late MVA-CMDR boost. Front Immunol. (2020) 11. Available online at: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00719/full. (Accessed May 20, 2025)
48
HauserACarnellGHeldKSulbaranGTischbierekNRogersLet al. Stepwise conformational stabilization of a HIV-1 clade C consensus envelope trimer immunogen impacts the profile of vaccine-induced antibody responses. Vaccines. (2021) 9:750. doi: 10.3390/vaccines9070750
Summary
Keywords
HIV-1, vaccines, race, sex, antibody, HVTN 204
Citation
Mbuya W, Horvath A, Held K, Maganga L, Hoelscher M, Bekker L-G, Duerr A, Moodie Z, Churchyard G, Keefer MC, Viegas E, Moog C, Geldmacher C and Chachage M (2025) Effects of sex but not race and geographic origin on vaccine-induced HIV-specific antibody responses. Front. Immunol. 16:1601865. doi: 10.3389/fimmu.2025.1601865
Received
28 March 2025
Accepted
12 August 2025
Published
23 September 2025
Volume
16 - 2025
Edited by
Ramesh Akkina, Colorado State University, United States
Reviewed by
Lorna Leal, European Medicines Agency, Netherlands
Jacques L. Tamuzi, Stellenbosch University, South Africa
Updates
Copyright
© 2025 Mbuya, Horvath, Held, Maganga, Hoelscher, Bekker, Duerr, Moodie, Churchyard, Keefer, Viegas, Moog, Geldmacher and Chachage.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mkunde Chachage, mchachage@nimr-mmrc.org; chachage.mkunde@udsm.ac.tz
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.